Chenlin Feng
PhD candidate
- Name
- Mr. C. Feng MMed
- Telephone
- +31 71 527 2727
- c.feng@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0003-1984-0926
In 2015, I got my bachelor’s degree of preventive medicine at Shandong University, school of public health. From 2016 to 2019, I did my master’s project of pharmacology at Chinese Academy of Medical Science, in the group of Prof Jiandong Jiang. During this period, I worked on exploring the anti-cancer effect of natural products, especially on murine models of colorectal cancer. After that, sponsored by China Scholarship Council, I came to Leiden University and started my PhD project on G protein-coupled receptor pharmacology under the guidance of Prof Laura Heitman and Prof Erik Danen. I’m working on two members of GPCR, the adenosine A2a receptor and serotonin 5HT2C receptor, both of which are found to be involved in cancer progression. By investigating the ligand binding kinetics and functional effects on cell behavior of these receptors, as well as their mutants found in cancer patients, we want to further illustrate their potential role in cancer, and improve their druggability as anti-cancer targets.
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Medicinal Chemistry
- Feng C., Liu R., Brooks R., Wang X., Jespers W., Gorostiola Gonzalez M., Westen G.J. P. van, Danen E.H.J. & Heitman L.H. (2024), The effect of cancer-associated mutations on ligand binding and receptor function - a case for the 5-HT2C receptor, European Journal of Pharmacology 985: 177081.
- Feng C.L., Wang X., Jespers W., Liu R., Zamarbide Losada S.D., Gorostiola Gonzalez M., Westen G.J.P. van, Danen E.H.J. & Heitman L.H. (2022), Cancer-associated mutations of the adenosine A2A receptor have diverse influences on ligand binding and receptor functions, Molecules 27(15): 4676.